Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Study on the Safety, Pharmacokinetic Characteristics, and Preliminary Efficacy of SC0191 Combination Chemotherapy in Patients With Advanced Ovarian Cancer.

NCT06055348 is registered in ClinicalTrials.gov with Biocity Biopharmaceutics Co., Ltd. as lead sponsor.

NCT NCT06055348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06055348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Study on the Safety, Pharmacokinetic Characteristics, and Preliminary Efficacy of SC0191 Combination Chemotherapy in Patients With Advanced Ovarian Cancer.
Lead sponsor
Biocity Biopharmaceutics Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 30, 2023
Completion date
November 30, 2025
Enrollment
112 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian cancer, serous ovarian cancer